North Korean hackers are suspected to have carried out a cyberattack against British coronavirus vaccine developer AstraZeneca in recent weeks, Reuters revealed Friday citing two unnamed sources with knowledge of the matter.
"There is, first of all, only limited amount that can be said in a press release and, secondly, it really needs to be reviewed in terms of the data and questions asked about the data that come up in the course of the review".
Meanwhile, members of the scientific community have said the Food and Drug Administration is unlikely to issue approval with the current data, especially since the trials didn't take place in the US.
In another branch of the trial, in which 8,895 participants received two full doses, the vaccine was found to be 62 per cent effective at preventing disease. He said further evidence would probably be available next month but it was "a highly significant result even with the numbers that we have".
Following today's deal, the United Kingdom now has access to enough doses of Moderna's vaccine candidate for around 3.5 million people.
The companies said this request could potentially mean the vaccine could be rolled out to high-risk populations by the middle of December 2020.
Britain is set to approve the Covid-19 vaccine developed by BioNTech SE and Pfizer Inc next week and deliveries would begin within hours of the authorisation, the Financial Times reported yesterday. "Because what are you going to do with the 70 percent when you've got two that are 95 percent?"
"The headline result is the vaccine works and that's very exciting", Patrick Vallance said on Thursday during a news conference with Prime Minister Boris Johnson. Officials expect 40 million doses to be ready by the end of the year.
Dr. Howard Njoo, Canada's deputy chief public health officer, said Wednesday that the vaccine trial questions reinforces the need for regulators to do their due diligence in reviewing vaccine candidates.
"We have formally asked the regulator to assess the Oxford/AstraZeneca vaccine, to understand the data and determine whether it meets rigorous safety standards", said Health Secretary Matt Hancock, as reported by news agency AFP.
In the real world, a vaccine's effectiveness can be influenced by multiple, unpredictable factors including, for example: the rate of spread of a virus; how many, or few, people adhere to the optimum dosing schedule and timetable; how individuals' immune systems respond; whether the vaccine was stored at the correct temperature; whether people know, or don't know, if they've been exposed before.
"The FDA are the ones saying we don't like the look of this".